Resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been considered the primary cause of treatment failure and cancer recurrence in patients with EGFR-mutant non-small cell lung cancer (NSCLC). The gene discussed is EGFR; the disease is cancer.